secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2023-03-24T23:59:59+00:00
Accession:  0001104659-23-036273
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccitech reports net income of $5.3M for FY2022 vs $50.9M loss in 2021; revenue jumps to $44.7M
--------------------------------------------------------------------------------

- Net income attributable to shareholders of $5.3M ($0.14 diluted EPS) vs net loss of $50.9M ($1.94 loss) in 2021.
- Revenue of $44.7M, primarily from AstraZeneca Vaxzevria milestones/royalties, up from $0.3M in 2021.
- Cash of $194.4M at Dec 31, 2022, down from $214.1M; operating cash used $14.4M, capital expenditures $5.8M.
- R&D expenses of $42.4M (up 108% YoY) driven by VTP-300 HBV, SNAPvax programs, and headcount growth.
- Appointed Dr. Nadège Pelletier as CSO in Jan 2023; interim data readouts for VTP-300 and VTP-200 expected in Q1 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/0001104659-23-036273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465923036273/tm2310111d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-036273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer